MCKMEDIUM SIGNALFINANCIAL10-K

McKesson demonstrated substantially higher profitability and meaningfully expanded shareholder returns through increased buybacks and dividends.

The company's strong earnings growth enabled management to significantly increase capital returns to shareholders, with share buybacks growing notably and dividend payments up over 30%. This suggests robust cash generation capabilities and management confidence in the business outlook.

Comparing 2025-05-09 vs 2024-05-08View on EDGAR →
FINANCIAL ANALYSIS

McKesson delivered substantially higher profitability with both net income and operating income growing meaningfully year-over-year. The company deployed this strong cash generation toward enhanced shareholder returns, with buybacks increasing notably and dividends up over 30%. Despite higher debt levels, the reduced cash position reflects active capital deployment rather than operational stress, indicating disciplined capital allocation in a profitable operating environment.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+51%
$3.1B$4.8B

Share repurchases increased 51% — management returning capital, signals confidence in intrinsic value.

Net Income
P&L
+44.5%
$3.3B$4.8B

Net income grew 44.5% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+40.5%
$4.4B$6.2B

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

R&D Expense
P&L
+35.2%
$71.0M$96.0M

R&D investment increased 35.2% — signals commitment to future product development, though near-term margin impact.

Dividends Paid
Cash Flow
+30.5%
$131.0M$171.0M

Dividend payments increased 30.5% — management confidence in sustained cash generation.

Cash & Equivalents
Balance Sheet
-30.2%
$5.7B$4.0B

Cash declined 30.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Debt
Balance Sheet
+15.4%
$5.7B$6.5B

Debt rose 15.4% — additional borrowing for investment or operations; monitor coverage ratios.

LANGUAGE CHANGES
NEW — 2025-05-09
PRIOR — 2024-05-08
ADDED
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 124 9A.
Our RxTS segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies.
RxTS offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, and dispensing support services, in addition to third-party logistics and wholesale distribution support designed to benefit stakeholders.
During fiscal 2025, we completed the sale of Rexall and Well.ca businesses in Canada.
Refer to Financial Note 2, Business Acquisitions and Divestitures, , to the consolidated financial statements included in this Annual Report for more information.
+7 more — sign up free →
REMOVED
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 126 9A.
Our Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma.
RxTS also offers prescription price transparency, benefit insight, dispensing support services, as well as third-party logistics and wholesale distribution support designed to benefit stakeholders.
Health Mart provides franchisees support for operational excellence, managed care contracting, marketing, merchandising solutions, and clinical programs to enhance patient care.
Health Mart Atlas Comprehensive managed care services that help community pharmacies save time, access competitive reimbursement rates, and improve cash flow.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →